Search research articles
Contact Us
Filters
Showing results (701-710 of 781) with videos related to
Page
of 79
Sort By:
Nature Communications
|
October 23, 2025
Predicting hypotension, syncope, and fracture risk in patients indicated for antihypertensive treatment: the STRATIFY models
Constantinos Koshiaris, Ariel Wang, Lucinda Archer, et al.
Clinical Therapeutics
|
March 9, 2010
Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial
David S Small, Christopher D Payne, Prajakti Kothare, et al.
Diagnostic and Prognostic Research
|
January 9, 2023
BLOod Test Trend for cancEr Detection (BLOTTED): protocol for an observational and prediction model development study using English primary care electronic health record data
Pradeep S Virdee, Clare Bankhead, Constantinos Koshiaris, et al.
The Journal of Organic Chemistry
|
September 10, 2005
Practical synthesis of the new carbapenem antibiotic ertapenem sodium
J Michael Williams, Karel M J Brands, Renato T Skerlj, et al.
Infectious Diseases and Therapy
|
September 26, 2023
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
F D Richard Hobbs, Hugh Montgomery, Francisco Padilla, et al.
International Journal of Epidemiology
|
October 22, 2022
Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
Steven Kerr, Stuart Bedston, Declan T Bradley, et al.
Nature Communications
|
August 15, 2022
Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
Colin R Simpson, Steven Kerr, Srinivasa Vittal Katikireddi, et al.
The Lancet Regional Health. Europe
|
September 6, 2023
Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel cohort
Mark Joy, Utkarsh Agrawal, Xuejuan Fan, et al.
The Lancet. Microbe
|
April 26, 2026
Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC)
David M Lowe, Shengyuan Zhang, Samuel Ellis, et al.
BMC Cardiovascular Disorders
|
March 26, 2013
Targets and self-management for the control of blood pressure in stroke and at risk groups (TASMIN-SR): protocol for a randomised controlled trial
Claire O'Brien, Emma P Bray, Stirling Bryan, et al.
Page
of 79
Search research articles
Search
Showing results (701-710 of 781) with videos related to
Sort By:
Page
of 79
Nature Communications
|
October 23, 2025
Predicting hypotension, syncope, and fracture risk in patients indicated for antihypertensive treatment: the STRATIFY models
Constantinos Koshiaris, Ariel Wang, Lucinda Archer, et al.
Clinical Therapeutics
|
March 9, 2010
Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial
David S Small, Christopher D Payne, Prajakti Kothare, et al.
Diagnostic and Prognostic Research
|
January 9, 2023
BLOod Test Trend for cancEr Detection (BLOTTED): protocol for an observational and prediction model development study using English primary care electronic health record data
Pradeep S Virdee, Clare Bankhead, Constantinos Koshiaris, et al.
The Journal of Organic Chemistry
|
September 10, 2005
Practical synthesis of the new carbapenem antibiotic ertapenem sodium
J Michael Williams, Karel M J Brands, Renato T Skerlj, et al.
Infectious Diseases and Therapy
|
September 26, 2023
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
F D Richard Hobbs, Hugh Montgomery, Francisco Padilla, et al.
International Journal of Epidemiology
|
October 22, 2022
Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
Steven Kerr, Stuart Bedston, Declan T Bradley, et al.
Nature Communications
|
August 15, 2022
Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
Colin R Simpson, Steven Kerr, Srinivasa Vittal Katikireddi, et al.
The Lancet Regional Health. Europe
|
September 6, 2023
Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel cohort
Mark Joy, Utkarsh Agrawal, Xuejuan Fan, et al.
The Lancet. Microbe
|
April 26, 2026
Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC)
David M Lowe, Shengyuan Zhang, Samuel Ellis, et al.
BMC Cardiovascular Disorders
|
March 26, 2013
Targets and self-management for the control of blood pressure in stroke and at risk groups (TASMIN-SR): protocol for a randomised controlled trial
Claire O'Brien, Emma P Bray, Stirling Bryan, et al.
Page
of 79